CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(01): 22-26
DOI: 10.4103/sajc.sajc_173_18
ORIGINAL ARTICLE: GI Cancers

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study

Anant Ramaswamy
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vikas Ostwal
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Nikhil Pande
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Atul Sharma
Department of Medical Oncology, Dr. B. R. A IRCH, AIIMS, New Delhi
,
Shekar Patil
Department of Medical Oncology, HCG, Bengaluru, Karnataka
,
Ravi Thippeswamy
Department of Medical Oncology, Sri Shankara Cancer Hospital, Bengaluru, Karnataka
,
Nikhil Ghadyalpatil
Department of Medical Oncology, Yashoda Cancer Institute, Hyderabad, Telangana
,
Rakesh Roy
Saroj Gupta Cancer Centre and Research Institute, Kolkata, West Bengal
,
Harish Peshwe
Department of Gastroenterology and Hepatology, Healthway Hospitals, Panjim, Goa
,
Bhavesh Poladia
Thangam Cancer Center, Namakkal, Tamil Nadu
,
Deepan Rajamanickam
Thangam Cancer Center, Namakkal, Tamil Nadu
,
Bharat Rangarajan
Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu
,
P. R. Neelesh Reddy
Department of Medical Oncology, Columbia Asia Hospital, Bengaluru, Karnataka
,
Vimal Pandita
Department of Medical Oncology, Max Superspeciality Hospital, Dehradun, Uttarakhand
,
Ashis Mukherjee
Department of Oncology, Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal
,
Aniket Thoke
Department of Oncology, Sanjeevani CBCC USA Cancer Hospital, Raipur, Chhattisgarh
,
Abhijit Sarkar
Saroj Gupta Cancer Center and Research Institute, Kolkata, West Bengal
,
C. T. Satish
Department of Medical Oncology, HCG, Bengaluru, Karnataka
,
H. Shashidara
Department of Medical Oncology, HCG, Bengaluru, Karnataka
,
S. D. Banavali
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
› Author Affiliations
Financial support and sponsorship: Nil.

Abstract

Background: Regorafenib is considered a standard of care as third-line therapy in metastatic colorectal cancers (mCRCs). Materials and Methods: The study was based on a computerized clinical data form sent to oncologists across the country for entry of anonymized patient data. The data entry form was conceived and generated by the coordinating center's (Tata Memorial Hospital) gastrointestinal medical oncologists and disseminated through personal contacts at academic conferences as well as through E-mail to various oncologists across India. Results: A total of 19 physicians contributed data resulting in 80 patients receiving regorafenib who were available for the evaluation of practice patterns. The median age was 55 years (range: 24–75). Majority had received oxaliplatin-based (97.5%), irinotecan-based (87.5%), and targeted therapy (65%), previously. Patients were primarily started on reduced doses of regorafenib upfront (160 mg – 28.8%, 120 mg – 58.8%, and 80 mg – 12.5%). The median duration of treatment (treatment duration) with regorafenib was 3.1 months (range: 0.5–18), while the median progression free survival was 3.48 months (range: 2.6–4.3). Forty-five percent of patients required dose modifications due to toxicities, and the most common were (all grades) hand-foot syndrome (68.8%), fatigue (46.3%), mucositis (37.6%), and diarrhea (31.3%). Conclusions: Majority of physicians in this collaborative study from India used a lower dose of regorafenib at the outset in patients with mCRC. Despite a lower dose, there was a significant requirement for dose reduction. Duration of treatment with regorafenib as an efficacy end point in this study is similar to available data from other regions as it is the side effect profile.



Publication History

Publication Date:
21 December 2020 (online)

© 2019. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
  • 2 Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:619-29.
  • 3 Mercier J, Voutsadakis IA. A systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer. Anticancer Res 2017;37:5925-34.
  • 4 Osawa H. Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer. Mol Clin Oncol 2017;6:365-72.
  • 5 Giampieri R, Prete MD, Prochilo T, Puzzoni M, Pusceddu V, Pani F, et al. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. Sci Rep 2017;7:45703.
  • 6 WMA – The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. [Last accessed on 2018 Jan 25].
  • 7 Chew MH, Yeo SA, Ng ZP, Lim KH, Koh PK, Ng KH, et al. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. Int J Colorectal Dis 2010;25:1221-9.
  • 8 Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, et al. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol 2015;22:1226-35.
  • 9 Tamhankar AS, Ingle P, Saklani A. PWE-284 signet ring colorectal carcinoma (SRCC): Do we need to improve the treatment algorithm? Gut 2015;64 Suppl 1:A336-7.
  • 10 Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De'Souza A, et al. Colorectal cancer in India: An audit from a tertiary center in a low prevalence area. Indian J Surg Oncol 2017;8:484-90.
  • 11 Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011;48:391-6.
  • 12 Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, et al. Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan. J Clin Oncol 2018;36 4 Suppl: 557.
  • 13 Zanwar S, Ostwal V, Gupta S, Sirohi B, Toshniwal A, Shetty N, et al. Toxicity and early outcomes of regorafenib in multiply pre-treated metastatic colorectal adenocarcinoma-experience from a tertiary cancer centre in India. Ann Transl Med 2016;4:74.
  • 14 Meeting Library | Regorafenib dose Optimization Study (ReDOS): Randomized Phase II trial to Evaluate dosing Strategies for Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) – An ACCRU Network Study. Available from: https://www.meetinglibrary.asco.org/record/155600/abstract. [Last accessed on 2018 Feb 5].